Sorafenib

Kidney Cancer

Bayer and Onyx have ongoing clinical trials for individuals with kidney cancer. For a more comprehensive list of sorafenib clinical trials in a variety of tumor types, please visit clinicaltrials.gov or call 866-639-2827.

Phase 3 Study of Sorafenib Versus Sunitinib in Adjuvant Setting – ASSURE *

Study Design: Randomized, placebo-controlled study

Patients: Patients with advanced RCC that has been removed by surgery

Purpose: To compare the efficacy of sorafenib versus sunitinib versus placebo by assessing the differences in disease progression and overall survival

Location: Various sites in the United States and Canada

Phase 3 Study of Sorafenib for 3 years vs. 1 year in Adjuvant Setting – SORCE *

Study Design: Randomized, placebo-controlled study

Patients: Patients with advanced RCC that has been removed by surgery

Purpose: To compare the efficacy of sorafenib treatment for 3 years vs. sorafenib treatment for 1 year vs. placebo by assessing differences in disease-free survival, as well as evaluate other measures of efficacy and safety

Location: United Kingdom

* Not a company-sponsored trial